2022 Ethics Leads Safety 
European Pharmaceutical Review
JUNE 29, 2022
How does that impact the safety of the biologics? Safety is key to the development of any medicine, but the safety considerations linked to bioproduction are more complex because biologics are more sophisticated medicines than small molecules. This could lead to false positives or, even worse, false negatives! PathoQuest.
pharmaphorum
OCTOBER 14, 2022
— Circular Digital Health (DiCE project) (@circular_health) October 13, 2022. The WEEE Forum notes that out of 16 ethical EU principles for digital health developed by the French Presidency of the EU, four focus on environmental sustainability, including eco-design, reuse, and recycling.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
OCTOBER 27, 2023
Benefits of The Future Clinical Trials Bill Chiefly, the Bill’s goal is to increase patient participation and overall, ensure clinical trials have the highest levels of safety while enabling greater regulatory pragmatism, the author explained. If achieved, this would boost the UK’s competitiveness as a leading international site for trials.
Nixon Gwilt Law
APRIL 22, 2024
The rule aims to regulate and enhance the transparency, effectiveness, and safety of predictive DSIs used in healthcare settings, ensuring that these technologies are developed and managed responsibly. In a recent blog post, the FTC illustrated how an AI company’s TOUs and PPs might lead to enforcement action.
Pharmaceutical Technology
JANUARY 23, 2023
The few approvals within paediatrics can be seen to be contributing to the numerous challenges associated with these studies; the smaller patient population, in addition to special measures required to ensure the ethics and safety of these trials, which all leads to trial delays, extended studies, and higher costs.
PharmaKinnex
AUGUST 23, 2022
August 23, 2022. The pharmaceutical industry of 2022 is very different from the space that we all knew in 2012, 2016, or even 2020. Today, in 2022, the industry is changing again, and in some big, exciting ways. More convenience and safety? The Traditional Pharma Model Isn’t Working – It’s Time to Evolve!
European Pharmaceutical Review
MAY 2, 2023
Cancer remains a global threat with around 10 million people dying from the disease each year worldwide, making it the second leading cause of death. billion in 2022, the average projected return on investment (ROI) in R&D was just 1.2 1,2 In the EU, an estimated 2.7 The COVID-19 blueprint has shown a way forward.
Expert insights. Personalized for you.
82 
Let's personalize your content